By inhibiting glucose and sodium reabsorption, SGLT2 inhibitors reduce glomerular hydrostatic pressure and hyperfiltration, alleviating kidney stress and improving renal hemodynamics, even in patients with advanced CKD. This evidence concerns the gene SLC5A2 and chronic kidney disease.